Core Viewpoint - The company reported an estimated revenue of approximately 350 to 360 million yuan for the first half of 2025, reflecting a year-on-year growth of about 16.2% to 19.5% [1] Revenue Growth Drivers - The primary drivers of revenue growth include an expanded market share in the transcatheter aortic valve replacement (TAVR) market in China and a shift towards higher-end product offerings [1] - Strong performance of key neurointerventional products, including deeper market penetration of existing products and the successful launch of the newly approved YonFlow flow-directed mesh stent [1] TAVR Market Performance - During the reporting period, the company's TAVR product portfolio covered over 720 medical institutions, with a total of more than 2050 TAVR implants, representing a year-on-year increase of approximately 18.8% [1]
沛嘉医疗-B上半年收入同比增长约16.2%—19.5%